Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CD24Fc When Administered Intravenously in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Efprezimod alfa (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors OncoImmune
- 09 Feb 2016 New trial record